

**Conclusions:** Overall, rTMS appear to provide significant therapeutic benefits for patients with TRD through the reduction of depressive symptoms. However, while there is progressive evidence in support of rTMS in TRD, more research is needed to define the standardized protocols of rTMS application in terms of localization, frequency, intensity, and pulse parameters to realize its full potency in TRD.

**Disclosure of Interest:** None Declared

#### EPV0439

### Adjunctive Therapy of Text4Support for Treatment-Resistant Depression Patients Receiving Repetitive Transcranial Magnetic Stimulation. A Multicenter Randomized Controlled Pilot Trial

M. K. Adu<sup>1\*</sup>, R. da Luz Dias<sup>2</sup>, B. Agyapong<sup>3</sup>, M. Flynn<sup>1</sup>, S. Hassan<sup>1</sup>, S. Sridharan<sup>1</sup>, M. K. White<sup>1</sup> and V. Agyapong<sup>1</sup>

<sup>1</sup>Psychiatry; <sup>2</sup>Dalhousie University, Halifax NS, Halifax and <sup>3</sup>Psychiatry, University of Alberta, Edmonton, Canada

\*Corresponding author.

doi: 10.1192/j.eurpsy.2023.1774

**Introduction:** Despite several treatment strategies for treatment-resistant depression (TRD) exist, including the use of repetitive transcranial magnetic stimulation (rTMS), new therapeutic options are being introduced. Text4Support is a form of cognitive behavior therapy that allows patients with depression to receive daily supportive text messages that seek to correct or alter negative thought patterns through positive reinforcement. Text4Support is deemed a useful augmentation treatment strategy for patients with TRD. It is however currently unknown if adding the Text4Support intervention will enhance patients with TRD's response to rTMS treatments

**Objectives:** This study aims to assess the initial comparative clinical effectiveness of rTMS when used with and without the Text4Support program as an innovative patient-centered intervention for the management of participants diagnosed with TRD.

**Methods:** This study is a multicentered prospective, parallel-design, two-arm, rater-blinded randomized controlled pilot trial. In total, 200 participants diagnosed with TRD will be randomized to one of two treatment arms (rTMS alone and rTMS with Text4Support). Participants in each arm will be made to complete evaluation measures at baseline, 1,3, and 6 months. The primary outcome measure will be the mean change to scores on the Hamilton Depression Rating Scale. Patient service utilization data and clinician-rated measures will also be used to gauge patient progress. Patient data will be analyzed with descriptive statistics, repeated measures, and correlational analyses.

**Results:** The result of the study is expected to be available 18 months after the start of recruitment. We hypothesize that participants enrolled in the rTMS plus Text4Support intervention will achieve superior outcomes compared with participants enrolled in the rTMS treatment alone.

**Conclusions:** The concomitant application of the combination of these two treatment techniques has not been investigated previously. Therefore, we hope that this project will provide a concrete base of data to evaluate the practical application and efficacy of using a novel combination of these two treatment modalities.

**Disclosure of Interest:** None Declared

#### EPV0440

### Comparative Effectiveness of Daily Supportive Text Messages Versus Email Messages for Patients with Depression. Randomized Hybrid Type II Effectiveness-Implementation Trial

M. K. Adu<sup>1\*</sup>, R. Shalaby<sup>2</sup>, E. Eboime<sup>2</sup> and V. Agyapong<sup>1</sup>

<sup>1</sup>Psychiatry, Dalhousie University, Halifax NS, Halifax and <sup>2</sup>Psychiatry, University of Alberta, Edmonton, Canada

\*Corresponding author.

doi: 10.1192/j.eurpsy.2023.1775

**Introduction: Background:** Major depressive disorder (MDD) is a global health problem accounting for about 40.5% of disability-adjusted life years caused by mental and substance use disorders. Barriers to accessing healthcare services have been reported, highlighting the need for innovative, accessible, and cost-effective psychological interventions. Several clinical trials have proven the effectiveness of supportive SMS text messaging in ameliorating depressive symptoms, however, this approach can only be accessible to individuals having cell phones.

**Objectives:** This paper aims to evaluate the effectiveness, feasibility, and user satisfaction of daily supportive email messaging as a non-inferior intervention compared to daily supportive text messaging as an add-on treatment for patients with depression.

**Methods:** This trial will be carried out using a hybrid type II implementation-effectiveness design. In addition to the usual care, patients with depression will be randomized to receive either supportive text messages or supportive email messages. The messages in both groups will have the same content and will be provided daily for 6 months. The implementation evaluation will be guided by the Consolidated Framework for Implementation Research and the RE-AIM (Reach, Effectiveness, Adoption, Implementation, and Maintenance) framework. Descriptive and inferential statistics will be employed in the analysis of the quantitative outcome measures, while thematic analysis will be used for Qualitative data.

**Results:** The results are expected to be available 18 months after the start of recruitment. The results will highlight the feasibility, acceptability, and effectiveness of using automated emails as a strategy for delivering supportive messages to patients with depression as non-inferior to text messaging.

**Conclusions:** The outcome of this trial will have a translational impact on routine patient care and access to mental health, as well as potentially support mental health policy decision-making for health care resource allocation.

**Disclosure of Interest:** None Declared

#### EPV0441

### Risk factors for psychiatric readmission among inpatients with major depressive disorder: A patient-chart based study

H. Al-Haboobi<sup>1</sup>, M. Ioannou<sup>1,2\*</sup>, M. Ben Saleh<sup>1</sup>, A. E. Bakken Wold<sup>2</sup>, S. Berg<sup>2</sup>, S. Patraskovic<sup>2</sup>, Z. Szabó<sup>2</sup> and S. Steingrímsson<sup>1,2</sup>

<sup>1</sup>Institute of Neuroscience and Physiology, University of Gothenburg, Sahlgrenska Academy and <sup>2</sup>Psykiatri Affektiva, Department of Psychiatry, Sahlgrenska University Hospital, Gothenburg, Sweden

\*Corresponding author.

doi: 10.1192/j.eurpsy.2023.1776